Information Provided By: 
Fly News Breaks for February 20, 2018
SHPG
Feb 20, 2018 | 08:56 EDT
SunTrust analyst John Boris lowered his price target on Shire to $190, citing expectations of lower Factor VIII sales from higher Hemlibra risk along with higher costs associated with Covington manufacturing facility. The analyst keeps his Buy rating, saying the expected second-half of 2018 launch of Lanadelumab, as well as the strategic decision on the Neuroscience business, are potential upside catalysts for Shire.
News For SHPG From the Last 2 Days
There are no results for your query SHPG
